Clinical Research Directory
Browse clinical research sites, groups, and studies.
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Sponsor: Hospital Authority, Hong Kong
Summary
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Official title: Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-08-21
Completion Date
2027-02-01
Last Updated
2025-10-01
Healthy Volunteers
No
Interventions
Faricimab Injection [Vabysmo]
A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.
Locations (1)
Department of Ophthalmology, United Chrisitian Hospital
Hong Kong, Hong Kong